Adverse Childhood Experiences Are Associated with Cardiometabolic Risk among Hispanic American Adolescents - 22/09/21
Abstract |
Objective |
To assess the relationship between adverse childhood experiences (ACEs) and cardiometabolic risk among Hispanic adolescents.
Study design |
This cross-sectional study was conducted at an academic research center in Gainesville, Florida. Participants were locally recruited, and data were collected from June 2016 to July 2018. Participants (n = 133, 60.2% female) were healthy adolescents aged 15-21 years who self-identified as Hispanic, were born in the US, and had a body mass index (BMI) between ≥18.5 and ≤40 kg/m2. Primary outcomes were BMI, body fat percentage, waist circumference, and resting blood pressure. Associations between ACEs and cardiometabolic measures were assessed by multivariable logistic regression models, which controlled for sex, age, parental education, and food insecurity. Results were sex-stratified to assess potential variations.
Results |
Reporting ≥4 ACEs (28.6%) was significantly associated with a greater BMI (P = .004), body fat percentage (P = .02), and diastolic blood pressure (P = .05) compared with reporting <4 ACEs. Female participants reporting ≥4 ACEs were significantly more likely to have a greater BMI (P = .04) and body fat percentage (P = .03) whereas male participants reporting ≥4 ACEs were significantly more likely to have a greater BMI (P = .04), systolic blood pressure (P = .03), and diastolic blood pressure (P = .03).
Conclusions |
Hispanic adolescent participants who experienced ≥4 ACEs were more likely to have elevated risk markers of obesity and cardiometabolic disease. Further research is needed to elucidate the physiological mechanisms driving these relationships.
Le texte complet de cet article est disponible en PDF.Keywords : Latinx, obesity, diabetes, cardiovascular, heart disease, trauma, abuse, violence, young adult]]
Abbreviations : ACE, BMI, BP, CVD, SES
Plan
Supported by the National Center for Advancing Translational Sciences of the National Institutes of Health (NIH; UL1TR001427). M.C. is an employee at WW International, Inc, and has consulted for Novo Nordisk but did not accept personal fees and is supported by the National Institutes of Health National Heart, Lung, and Blood Institute (K01HL141535 and R25HL126146). The other authors declare no conflicts of interest. |
Vol 237
P. 267 - octobre 2021 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?